{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:17:47Z","timestamp":1793719067207,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antipsychotic medication can reduce psychotic symptoms and risk of relapse in people with schizophrenia and related disorders, but it is not always effective and adverse effects can be significant. We know little of patients\u2019 views about continuing or discontinuing antipsychotic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To explore the views of people with schizophrenia and other psychotic disorders about continuing their antipsychotic medication or attempting to reduce or discontinue this medication with clinical support.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected quantitative and qualitative data by conducting semi-structured interviews in London, UK. Factors predicting a desire to discontinue medication were explored. Content analysis of qualitative data was undertaken.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We interviewed 269 participants. 33% (95% CI, 27 to 39%) were content with taking long-term antipsychotic medication. Others reported they took it reluctantly (19%), accepted it on a temporary basis (24%) or actively disliked it (18%). 31% (95% CI, 25 to 37%) said they would like to try to stop medication with professional support, and 45% (95% CI, 39 to 51%) wanted the opportunity to reduce medication. People who wanted to discontinue had more negative attitudes towards the medication but were otherwise similar to other participants. Wanting to stop or reduce medication was motivated mainly by adverse effects and health concerns. Professional support was identified as potentially helpful to achieve reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This large study reveals that patients are commonly unhappy about the idea of taking antipsychotics on a continuing or life-long basis. Professional support for people who want to try to reduce or stop medication is valued.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-03822-5","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T22:02:15Z","timestamp":1647381735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders"],"prefix":"10.1186","volume":"22","author":[{"given":"Nadia E.","family":"Crellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Morant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pinfold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Darton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gruenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Freudenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacki L.","family":"Stansfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"3822_CR1","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition.\u00a0Am J Psychiatry. 2004;161(2):1-56."},{"key":"3822_CR2","volume-title":"Psychosis and schizophrenia in adults: treatment and management","author":"National Institute for Health and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: treatment and management. London: NICE; 2014."},{"issue":"9","key":"3822_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"key":"3822_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","volume":"215","author":"Y Shimomura","year":"2020","unstructured":"Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res. 2020;215:8\u201316. https:\/\/doi.org\/10.1016\/j.schres.2019.09.013.","journal-title":"Schizophr Res"},{"issue":"10","key":"3822_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian Meta-analysis, and Meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927\u201342. https:\/\/doi.org\/10.1176\/appi.ajp.2017.16121358.","journal-title":"Am J Psychiatry"},{"key":"3822_CR6","doi-asserted-by":"publisher","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;16(5). https:\/\/doi.org\/10.1002\/14651858.CD008016.pub2.","DOI":"10.1002\/14651858.CD008016.pub2"},{"key":"3822_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.schres.2020.02.009","volume":"225","author":"RB Zipursky","year":"2020","unstructured":"Zipursky RB, Odejayi G, Agid O, Remington G. You say \u201cschizophrenia\u201d and I say \u201cpsychosis\u201d: just tell me when I can come off this medication. Schizophr Res. 2020;225:39\u201346. https:\/\/doi.org\/10.1016\/j.schres.2020.02.009.","journal-title":"Schizophr Res"},{"key":"3822_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","volume":"23","author":"NA Buckley","year":"2000","unstructured":"Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000;23:215\u201328. https:\/\/doi.org\/10.2165\/00002018-200023030-00004.","journal-title":"Drug Saf"},{"key":"3822_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0447.2009.01356.x","volume":"120","author":"J Moncrieff","year":"2009","unstructured":"Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of internet data. Acta Psychiatr Scand. 2009;120:102\u201311. https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01356.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"3822_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","volume":"174","author":"AP Rajkumar","year":"2017","unstructured":"Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatr. 2017;174(7):686\u201394. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16040442.","journal-title":"Am J Psychiatr"},{"key":"3822_CR11","doi-asserted-by":"publisher","unstructured":"Bjornestad J, Lavik KO, Davidson L, Hjeltnes A, Moltu C, Veseth M. Antipsychotic treatment \u2013 a systematic literature review and meta-analysis of qualitative studies. J Ment Health. 2019:1\u201311. https:\/\/doi.org\/10.1080\/09638237.2019.1581352.","DOI":"10.1080\/09638237.2019.1581352"},{"key":"3822_CR12","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/ppa.s270020","volume":"14","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, O\u2019sullivan AK, Maher S, Bjorner JB, et al. Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043. https:\/\/doi.org\/10.2147\/ppa.s270020.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"3822_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00127-019-01819-2","volume":"55","author":"J Thompson","year":"2020","unstructured":"Thompson J, Stansfeld JL, Cooper RE, Morant N, Crellin NE, Moncrieff J. Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative data. Soc Psychiatry Psychiatr Epidemiol. 2020;55(2):151\u201364. https:\/\/doi.org\/10.1007\/s00127-019-01819-2.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"3822_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","volume":"54","author":"A Viguera","year":"1997","unstructured":"Viguera A, Baldessarini R, Hegarty J, van Kammen D, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54:49\u201355. https:\/\/doi.org\/10.1001\/archpsyc.1997.01830130055011.","journal-title":"Arch Gen Psychiatry"},{"key":"3822_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archpsyc.64.2.242","volume":"64","author":"DPJ Osborn","year":"2007","unstructured":"Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and Cancer mortality in people with severe mental illness from the United Kingdom\u2019s general practice research database. Arch Gen Psychiatry. 2007;64:9.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"3822_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-013-0079-5","volume":"27","author":"A Cerovecki","year":"2013","unstructured":"Cerovecki A, Musil R, Klimke A, Seem\u00fcller F, Haen E, Schennach R, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27(7):545\u201372. https:\/\/doi.org\/10.1007\/s40263-013-0079-5.","journal-title":"CNS Drugs"},{"key":"3822_CR17","doi-asserted-by":"publisher","first-page":"e1001861","DOI":"10.1371\/journal.pmed.1001861","volume":"12","author":"J Moncrieff","year":"2015","unstructured":"Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med. 2015;12:e1001861. https:\/\/doi.org\/10.1371\/journal.pmed.1001861.","journal-title":"PLoS Med"},{"issue":"8","key":"3822_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"J Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H. 20-year Nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765\u201373. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091001.","journal-title":"Am J Psychiatry"},{"issue":"14","key":"3822_CR19","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1017\/S0033291714000610","volume":"44","author":"M Harrow","year":"2014","unstructured":"Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007\u201316. https:\/\/doi.org\/10.1017\/S0033291714000610.","journal-title":"Psychol Med"},{"key":"3822_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2016.03.002","volume":"36","author":"JM Moilanen","year":"2016","unstructured":"Moilanen JM, Haapea M, J\u00e4\u00e4skel\u00e4inen E, Veijola JM, Isohanni MK, Koponen HJ, et al. Long-term antipsychotic use and its association with outcomes in schizophrenia \u2013 the northern Finland birth cohort 1966. Eur Psychiatry. 2016;36:7\u201314. https:\/\/doi.org\/10.1016\/j.eurpsy.2016.03.002.","journal-title":"Eur Psychiatry"},{"key":"3822_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.schres.2016.10.030","volume":"182","author":"RS Wils","year":"2017","unstructured":"Wils RS, Gotfredsen DR, Hjorth\u00f8j C, Austin SF, Albert N, Secher RG, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017;182:42\u20138. https:\/\/doi.org\/10.1016\/j.schres.2016.10.030.","journal-title":"Schizophr Res"},{"key":"3822_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","volume":"70","author":"L Wunderink","year":"2013","unstructured":"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.19.","journal-title":"JAMA Psychiatry"},{"key":"3822_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","volume":"5","author":"CLM Hui","year":"2018","unstructured":"Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018;5:432\u201342. https:\/\/doi.org\/10.1016\/S2215-0366(18)30090-7.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"3822_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(18)30124-X","volume":"5","author":"RB Zipursky","year":"2018","unstructured":"Zipursky RB, Agid O, Remington G. Improving outcomes in schizophrenia by preventing early relapses. Lancet Psychiatry. 2018;5(5):384\u20136. https:\/\/doi.org\/10.1016\/S2215-0366(18)30124-X.","journal-title":"Lancet Psychiatry"},{"key":"3822_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291718003811","volume":"19","author":"J Moncrieff","year":"2019","unstructured":"Moncrieff J, Steingard S. A critical analysis of recent data on the long-term outcome of antipsychotic treatment. Psychol Med. 2019;19:1\u20134. https:\/\/doi.org\/10.1017\/S0033291718003811.","journal-title":"Psychol Med"},{"issue":"7","key":"3822_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2215-0366(21)00159-0","volume":"8","author":"JJ Luykx","year":"2021","unstructured":"Luykx JJ, Tiihonen J. Antipsychotic discontinuation: mind the patient and the real-world evidence. Lancet Psychiatry. 2021;8(7):555\u20137. https:\/\/doi.org\/10.1016\/S2215-0366(21)00159-0.","journal-title":"Lancet Psychiatry"},{"key":"3822_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1017\/S0033291701003749","volume":"31","author":"MC Angermeyer","year":"2001","unstructured":"Angermeyer MC, L\u00f6ffler W, M\u00fcller P, Schulze B, Priebe S. Patients\u2019 and relatives\u2019 assessment of clozapine treatment. Psychol Med. 2001;31:509\u201317. https:\/\/doi.org\/10.1017\/S0033291701003749.","journal-title":"Psychol Med"},{"key":"3822_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1049732316634047","volume":"27","author":"GL Geyt","year":"2017","unstructured":"Geyt GL, Awenat Y, Tai S, Haddock G. Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res. 2017;27:559\u201372. https:\/\/doi.org\/10.1177\/1049732316634047.","journal-title":"Qual Health Res"},{"key":"3822_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/09638237.2017.1370637","volume":"27","author":"N Morant","year":"2018","unstructured":"Morant N, Azam K, Johnson S, Moncrieff J. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health. 2018;27:322\u20138. https:\/\/doi.org\/10.1080\/09638237.2017.1370637.","journal-title":"J Ment Health"},{"issue":"10","key":"3822_CR30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"3822_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.4088\/jcp.v67n1008","volume":"67","author":"M Valenstein","year":"2006","unstructured":"Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542\u201350. https:\/\/doi.org\/10.4088\/jcp.v67n1008.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3822_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","volume":"23","author":"PM Haddad","year":"2014","unstructured":"Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;23(5):43\u201362. https:\/\/doi.org\/10.2147\/PROM.S42735.","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"3822_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","volume":"114","author":"J Moncrieff","year":"2006","unstructured":"Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3\u201313. https:\/\/doi.org\/10.1111\/j.1600-0447.2006.00787.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"3822_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","volume":"86","author":"G Chouinard","year":"2017","unstructured":"Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, et al. Antipsychotic-induced dopamine Supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86(4):189\u2013219. https:\/\/doi.org\/10.1159\/000477313.","journal-title":"Psychother Psychosom"},{"key":"3822_CR35","doi-asserted-by":"publisher","first-page":"e030912","DOI":"10.1136\/bmjopen-2019-030912","volume":"9","author":"J Moncrieff","year":"2019","unstructured":"Moncrieff J, Lewis G, Freemantle N, Johnson S, Barnes TRE, Morant N, et al. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (research into antipsychotic discontinuation and reduction). BMJ Open. 2019;9:e030912. https:\/\/doi.org\/10.1136\/bmjopen-2019-030912.","journal-title":"BMJ Open"},{"key":"3822_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177\u201383. https:\/\/doi.org\/10.1017\/S0033291700050182.","journal-title":"Psychol Med"},{"key":"3822_CR37","volume-title":"IBM SPSS statistics for Macintosh","author":"IBM Corp","year":"2017","unstructured":"Corp IBM. IBM SPSS statistics for Macintosh. Armonk: IBM Corp; 2017."},{"key":"3822_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/07399339209516006","volume":"13","author":"B Downe-Wambolt","year":"1992","unstructured":"Downe-Wambolt B. Content analysis: method, applications and issues. Health Care Women Int. 1992;13:313\u201321. https:\/\/doi.org\/10.1080\/07399339209516006.","journal-title":"Health Care Women Int"},{"key":"3822_CR39","doi-asserted-by":"publisher","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2015:1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","DOI":"10.1177\/1049732305276687"},{"issue":"6","key":"3822_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3109\/01612840.2015.1132289","volume":"37","author":"DI Velligan","year":"2016","unstructured":"Velligan DI, Roberts DL, Sierra C, Fredrick MM, Roach MJ. What patients with severe mental illness transitioning from hospital to community have to say about care and shared decision-making. Issues Ment Health Nurs. 2016;37(6):400\u20135. https:\/\/doi.org\/10.3109\/01612840.2015.1132289.","journal-title":"Issues Ment Health Nurs"},{"key":"3822_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1600-0447.2008.01279.x","volume":"119","author":"H J\u00f3nsd\u00f3ttir","year":"2009","unstructured":"J\u00f3nsd\u00f3ttir H, Friis S, Horne R, Pettersen KI, Reikvam \u00c5, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009;119:78\u201384. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01279.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"3822_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-020-02767-x","volume":"20","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Velligan DI, Weiden PJ, O\u2019Sullivan AK, Yarlas A, Bayliss M. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020;20(1):1\u20132. https:\/\/doi.org\/10.1186\/s12888-020-02767-x.","journal-title":"BMC psychiatry"},{"key":"3822_CR43","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/ppa.s270020","volume":"14","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, O\u2019sullivan AK, Maher S, Bjorner JB, et al. Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043. https:\/\/doi.org\/10.2147\/ppa.s270020.","journal-title":"Patient Prefer Adherence"},{"key":"3822_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jad.2008.11.004","volume":"116","author":"J Clatworthy","year":"2009","unstructured":"Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R. Understanding medication non-adherence in bipolar disorders using a necessity-concerns framework. J Affect Disord. 2009;116:51\u20135. https:\/\/doi.org\/10.1016\/j.jad.2008.11.004.","journal-title":"J Affect Disord"},{"issue":"4","key":"3822_CR45","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","volume":"47","author":"MA Horowitz","year":"2021","unstructured":"Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull. 2021;47(4):1116\u201329. https:\/\/doi.org\/10.1093\/schbul\/sbab017.","journal-title":"Schizophr Bull"},{"key":"3822_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1742395310369018","volume":"6","author":"R Horne","year":"2010","unstructured":"Horne R, Clatworthy J, Hankins M. On behalf of the ASCOT investigators. High adherence and concordance within a clinical trial of antihypertensives. Chronic Illn. 2010;6:243\u201351. https:\/\/doi.org\/10.1177\/1742395310369018.","journal-title":"Chronic Illn"},{"key":"3822_CR47","doi-asserted-by":"publisher","first-page":"e0218711","DOI":"10.1371\/journal.pone.0218711","volume":"14","author":"RE Cooper","year":"2019","unstructured":"Cooper RE, Hanratty \u00c9, Morant N, Moncrieff J. Mental health professionals\u2019 views and experiences of antipsychotic reduction and discontinuation. PLoS One. 2019a;14:e0218711. https:\/\/doi.org\/10.1371\/journal.pone.0218711.","journal-title":"PLoS One"},{"key":"3822_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125319836566","volume":"9","author":"L Wunderink","year":"2019","unstructured":"Wunderink L. Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Ther Advanc Psychopharmacol. 2019;9:1\u201314. https:\/\/doi.org\/10.1177\/2045125319836566.","journal-title":"Ther Advanc Psychopharmacol"},{"issue":"11","key":"3822_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","volume":"74","author":"JW Newcomer","year":"2013","unstructured":"Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry. 2013;74(11):1108\u201320.","journal-title":"J Clin Psychiatry"},{"key":"3822_CR50","doi-asserted-by":"publisher","unstructured":"Cooper RE, Laxhman N, Crellin N, Moncrieff J, Priebe S. Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: a systematic review. Schizophr Res. 2019b;S0920996419301823. https:\/\/doi.org\/10.1016\/j.schres.2019.05.020.","DOI":"10.1016\/j.schres.2019.05.020"},{"key":"3822_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12888-016-0921-7","volume":"16","author":"J Moncrieff","year":"2016","unstructured":"Moncrieff J, Azam K, Johnson S, Marston L, Morant N, Darton K, et al. Results of a pilot cluster randomised trial of the use of a medication review tool for people taking antipsychotic medication. BMC Psychiatry. 2016;16:205. https:\/\/doi.org\/10.1186\/s12888-016-0921-7.","journal-title":"BMC Psychiatry"},{"key":"3822_CR52","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/0020764017733764","volume":"63","author":"S Ramon","year":"2017","unstructured":"Ramon S, Morant N, Stead U, Perry B. Shared decision-making for psychiatric medication: a mixed-methods evaluation of a UK training programme for service users and clinicians. Int J Soc Psychiatry. 2017;63:763\u201372. https:\/\/doi.org\/10.1177\/0020764017733764.","journal-title":"Int J Soc Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-03822-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T22:04:08Z","timestamp":1647381848000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-03822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3822"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-03822-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"13 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all participants. Ethical approval was provided by the East of Scotland Research Ethics Service (Research Ethics Committee reference: 15\/ES\/0163).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not relevant as no details, images, or videos relating to an individual person were published in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GL has received funds in the course of acting as an expert witness in a case involving antidepressant withdrawal symptoms. No other authors have anything to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}